Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway
Pharmaceutical Sciences and Drug Design · 2025
DOI: 10.51847/1hgehtnb9j ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2025. Verfasst von Sara Lindholm und 1 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Sodium cantharidinate (SC) has demonstrated efficacy in treating lung cancer in China, yet its effects in cervical cancer (CC)—a major cause of female reproductive cancer mortality—remain largely unexplored. This study investigates SC’s anti-cancer activity in CC and explores the molecular mechanisms involved. DDP-resistant Caski-1 and ME180 cervical cancer cell lines were established and treated with SC to assess its impact on cell proliferation. Potential molecular targets of SC were predicted
Zitieren
APA
Lindholm, S., & Berg, K. (2025). Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway. Pharmaceutical Sciences and Drug Design. https://doi.org/10.51847/1hgehtnb9j
Vancouver
Lindholm S, Berg K. Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway. Pharmaceutical Sciences and Drug Design. 2025. doi:10.51847/1hgehtnb9j
BibTeX
@article{Lindholm2025,
author = {Lindholm, Sara and Berg, Karin},
title = {Sodium Cantharidinate Enhances Cisplatin Sensitivity in Cervical Cancer via PTPN1-Mediated Inhibition of the PI3K/AKT Pathway},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2025},
doi = {10.51847/1hgehtnb9j}
}
EUVIMED